Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells.

Garand C, Guay D, Sereduk C, Chow D, Tsofack SP, Langlois M, Perreault E, Yin HH, Lebel M.

Cancer Sci. 2011 Jul;102(7):1410-7. doi: 10.1111/j.1349-7006.2011.01948.x. Epub 2011 May 5.

2.

YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification.

Davies AH, Barrett I, Pambid MR, Hu K, Stratford AL, Freeman S, Berquin IM, Pelech S, Hieter P, Maxwell C, Dunn SE.

Oncogene. 2011 Aug 25;30(34):3649-60. doi: 10.1038/onc.2011.82. Epub 2011 Mar 21.

3.

Vigilance and validation: Keys to success in RNAi screening.

Sigoillot FD, King RW.

ACS Chem Biol. 2011 Jan 21;6(1):47-60. doi: 10.1021/cb100358f. Epub 2010 Dec 28. Review.

4.
5.

Twist1 and Y-box-binding protein-1 promote malignant potential in bladder cancer cells.

Shiota M, Yokomizo A, Itsumi M, Uchiumi T, Tada Y, Song Y, Kashiwagi E, Masubuchi D, Naito S.

BJU Int. 2011 Jul;108(2 Pt 2):E142-9. doi: 10.1111/j.1464-410X.2010.09810.x. Epub 2010 Nov 17.

6.

Antisense treatment in human prostate cancer and melanoma.

Di Cresce C, Koropatnick J.

Curr Cancer Drug Targets. 2010 Sep;10(6):555-65. Review.

PMID:
20482488
7.

hnRNP M interacts with PSF and p54(nrb) and co-localizes within defined nuclear structures.

Marko M, Leichter M, Patrinou-Georgoula M, Guialis A.

Exp Cell Res. 2010 Feb 1;316(3):390-400. doi: 10.1016/j.yexcr.2009.10.021. Epub 2009 Oct 27.

PMID:
19874820
8.

Involvement of p54(nrb), a PSF partner protein, in DNA double-strand break repair and radioresistance.

Li S, Kuhne WW, Kulharya A, Hudson FZ, Ha K, Cao Z, Dynan WS.

Nucleic Acids Res. 2009 Nov;37(20):6746-53. doi: 10.1093/nar/gkp741. Epub 2009 Sep 16.

9.

The interaction profile of homologous recombination repair proteins RAD51C, RAD51D and XRCC2 as determined by proteomic analysis.

Rajesh C, Gruver AM, Basrur V, Pittman DL.

Proteomics. 2009 Aug;9(16):4071-86. doi: 10.1002/pmic.200800977.

10.

p54nrb is a transcriptional corepressor of the progesterone receptor that modulates transcription of the labor-associated gene, connexin 43 (Gja1).

Dong X, Yu C, Shynlova O, Challis JR, Rennie PS, Lye SJ.

Mol Endocrinol. 2009 Aug;23(8):1147-60. doi: 10.1210/me.2008-0357. Epub 2009 May 7.

11.

Novel DNA mismatch-repair activity involving YB-1 in human mitochondria.

de Souza-Pinto NC, Mason PA, Hashiguchi K, Weissman L, Tian J, Guay D, Lebel M, Stevnsner TV, Rasmussen LJ, Bohr VA.

DNA Repair (Amst). 2009 Jun 4;8(6):704-19. doi: 10.1016/j.dnarep.2009.01.021. Epub 2009 Mar 9.

12.

Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells.

Finkbeiner MR, Astanehe A, To K, Fotovati A, Davies AH, Zhao Y, Jiang H, Stratford AL, Shadeo A, Boccaccio C, Comoglio P, Mertens PR, Eirew P, Raouf A, Eaves CJ, Dunn SE.

Oncogene. 2009 Mar 19;28(11):1421-31. doi: 10.1038/onc.2008.485. Epub 2009 Jan 19.

PMID:
19151767
13.

Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer.

Martinez-Cardús A, Martinez-Balibrea E, Bandrés E, Malumbres R, Ginés A, Manzano JL, Taron M, Garcia-Foncillas J, Abad A.

Mol Cancer Ther. 2009 Jan;8(1):194-202. doi: 10.1158/1535-7163.MCT-08-0659.

14.

Chromosome copy number analysis in screening for prognosis-related genomic regions in colorectal carcinoma.

Kurashina K, Yamashita Y, Ueno T, Koinuma K, Ohashi J, Horie H, Miyakura Y, Hamada T, Haruta H, Hatanaka H, Soda M, Choi YL, Takada S, Yasuda Y, Nagai H, Mano H.

Cancer Sci. 2008 Sep;99(9):1835-40. doi: 10.1111/j.1349-7006.2008.00881.x. Epub 2008 Jun 28.

15.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J.

J Clin Oncol. 2008 Apr 20;26(12):2013-9. doi: 10.1200/JCO.2007.14.9930. Erratum in: J Clin Oncol. 2008 Jun;26(18):3110. J Clin Oncol. 2009 Feb 1;27(4):653.

PMID:
18421054
16.

The human endonuclease III enzyme is a relevant target to potentiate cisplatin cytotoxicity in Y-box-binding protein-1 overexpressing tumor cells.

Guay D, Garand C, Reddy S, Schmutte C, Lebel M.

Cancer Sci. 2008 Apr;99(4):762-9. doi: 10.1111/j.1349-7006.2008.00739.x. Epub 2008 Feb 27.

17.

Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect.

Ui-Tei K, Naito Y, Zenno S, Nishi K, Yamato K, Takahashi F, Juni A, Saigo K.

Nucleic Acids Res. 2008 Apr;36(7):2136-51. doi: 10.1093/nar/gkn042. Epub 2008 Feb 11.

18.

Transcriptome profile of human colorectal adenomas.

Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer H, Laczko E, Kurowski MA, Bujnicki JM, Menigatti M, Luz J, Ranalli TV, Gomes V, Pastorelli A, Faggiani R, Anti M, Jiricny J, Clevers H, Marra G.

Mol Cancer Res. 2007 Dec;5(12):1263-75. doi: 10.1158/1541-7786.MCR-07-0267.

19.
20.

Supplemental Content

Support Center